Skip to content

Study · Case report or series · n = 1 · 2025

5 results

The Impact of Semaglutide on Metabolic Syndrome: A Case Report.

Joseph J

Cureus3 Jul 2025Cited by 1 (Europe PMC)

PMID40755669 (opens in a new tab)PMCIDPMC12317596 (opens in a new tab)DOI10.7759/cureus.87223 (opens in a new tab)PepBankPUB-40755669
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

This case describes a 44-year-old male with poorly controlled type 2 diabetes mellitus, dyslipidemia, and hypertension - hallmarks of metabolic syndrome - who demonstrated significant clinical improvement following the initiation of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), after discontinuing sitagliptin. The patient had previously been treated with multiple oral hypoglycemic agents and basal insulin, yet continued to have inadequate glycemic and lipid control. Upon replacing sitagliptin with semaglutide, he experienced marked reductions in glycated hemoglobin, low-density lipoprotein cholesterol, and urine albumin-creatinine ratio, along with improvements in liver enzyme levels and stable renal function. This case highlights the pleiotropic benefits of GLP-1 receptor agonists and supports their role in the comprehensive management of metabolic syndrome.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 44-year-old man with type 2 diabetes, replacing sitagliptin with semaglutide was followed by a marked reduction in glycated hemoglobin.

    In plain wordsIn one man with type 2 diabetes, switching from sitagliptin to semaglutide was followed by a marked fall in HbA1c.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c
    Study

    n = 1

    Comparator
    Sitagliptin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon replacing sitagliptin with semaglutide, he experienced marked reductions in glycated hemoglobin, low-density lipoprotein cholesterol, and urine albumin-creatinine ratio, along with improvements in liver enzyme levels and stable renal function.
    1 context sentence
    Summary · context
    This case describes a 44-year-old male with poorly controlled type 2 diabetes mellitus, dyslipidemia, and hypertension - hallmarks of metabolic syndrome - who demonstrated significant clinical improvement following the initiation of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), after discontinuing sitagliptin.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 44-year-old man with type 2 diabetes, replacing sitagliptin with semaglutide was followed by a marked reduction in LDL cholesterol.

    In plain wordsIn one man with type 2 diabetes, switching from sitagliptin to semaglutide was followed by a marked fall in LDL cholesterol.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL cholesterol
    Study

    n = 1

    Comparator
    Sitagliptin
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon replacing sitagliptin with semaglutide, he experienced marked reductions in glycated hemoglobin, low-density lipoprotein cholesterol, and urine albumin-creatinine ratio, along with improvements in liver enzyme levels and stable renal function.
    1 context sentence
    Summary · context
    This case describes a 44-year-old male with poorly controlled type 2 diabetes mellitus, dyslipidemia, and hypertension - hallmarks of metabolic syndrome - who demonstrated significant clinical improvement following the initiation of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), after discontinuing sitagliptin.
  3. 03HumanCase report or seriesEfficacy outcome

    In a 44-year-old man with type 2 diabetes, replacing sitagliptin with semaglutide was followed by a marked reduction in urine albumin-creatinine ratio.

    In plain wordsIn one man with type 2 diabetes, switching from sitagliptin to semaglutide was followed by a marked fall in urine albumin.

    Peptide
    Semaglutide
    Outcome
    DecreaseUrine albumin-creatinine ratio
    Study

    n = 1

    Comparator
    Sitagliptin
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon replacing sitagliptin with semaglutide, he experienced marked reductions in glycated hemoglobin, low-density lipoprotein cholesterol, and urine albumin-creatinine ratio, along with improvements in liver enzyme levels and stable renal function.
    1 context sentence
    Summary · context
    This case describes a 44-year-old male with poorly controlled type 2 diabetes mellitus, dyslipidemia, and hypertension - hallmarks of metabolic syndrome - who demonstrated significant clinical improvement following the initiation of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), after discontinuing sitagliptin.
  4. 04HumanCase report or seriesEfficacy outcome

    In a 44-year-old man with type 2 diabetes, replacing sitagliptin with semaglutide was followed by improved liver enzyme levels.

    In plain wordsIn one man with type 2 diabetes, switching from sitagliptin to semaglutide was followed by better liver enzyme levels.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver enzyme levels
    Study

    n = 1

    Comparator
    Sitagliptin
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon replacing sitagliptin with semaglutide, he experienced marked reductions in glycated hemoglobin, low-density lipoprotein cholesterol, and urine albumin-creatinine ratio, along with improvements in liver enzyme levels and stable renal function.
    1 context sentence
    Summary · context
    This case describes a 44-year-old male with poorly controlled type 2 diabetes mellitus, dyslipidemia, and hypertension - hallmarks of metabolic syndrome - who demonstrated significant clinical improvement following the initiation of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), after discontinuing sitagliptin.
  5. 05HumanCase report or seriesEfficacy outcome

    In a 44-year-old man with type 2 diabetes, renal function stayed stable after sitagliptin was replaced with semaglutide.

    In plain wordsIn one man with type 2 diabetes, kidney function stayed stable after switching from sitagliptin to semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeRenal function
    Study

    n = 1

    Comparator
    Sitagliptin
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Upon replacing sitagliptin with semaglutide, he experienced marked reductions in glycated hemoglobin, low-density lipoprotein cholesterol, and urine albumin-creatinine ratio, along with improvements in liver enzyme levels and stable renal function.
    1 context sentence
    Summary · context
    This case describes a 44-year-old male with poorly controlled type 2 diabetes mellitus, dyslipidemia, and hypertension - hallmarks of metabolic syndrome - who demonstrated significant clinical improvement following the initiation of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), after discontinuing sitagliptin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.